Literature DB >> 27571306

Modulation of autoimmune arthritis severity in mice by apolipoprotein E (ApoE) and cholesterol.

P Alvarez1, F Genre2, M Iglesias2, J J Augustin1,2, E Tamayo2, J C Escolà-Gil3, B Lavín4, F Blanco-Vaca3, R Merino1,2, J Merino2.   

Abstract

Apolipoprotein E (ApoE) deficiency promoted an exacerbation of autoimmune arthritis in mice by inducing proinflammatory immune responses. In this study we analysed the contribution of hypercholesterolaemia and/or the absence of ApoE anti-inflammatory properties, unrelated to its function in the control of cholesterol metabolism, towards the acceleration of arthritis in these mutant animals. The induction and severity of collagen type II-induced arthritis (CIA) were compared for B10.RIII wild-type (WT), B10.RIII.ApoE+/- , B10.RIII.ApoE-/- and B10.RIII.low-density lipoprotein receptor (LDLR-/- ) mice with different concentrations of circulating ApoE and cholesterol. A 50-70% reduction in serum levels of ApoE was observed in heterozygous B10.RIII.ApoE+/- mice in comparison to B10.RIII.WT, although both strains of mice exhibited similar circulating lipid profiles. This ApoE reduction was associated with an increased CIA severity that remained lower than in homozygous B10.RIII.ApoE-/- mice. An important rise in circulating ApoE concentration was observed in hypercholesterolaemic B10.RIII.LDLR-/- mice fed with a normal chow diet, and both parameters increased further with an atherogenic hypercholesterolaemic diet. However, the severity of CIA in B10.RIII.LDLR-/- mice was similar to that of B10.RIII.WT controls. In conclusion, by comparing the evolution of CIA between several strains of mutant mice with different levels of serum ApoE and cholesterol, our results demonstrate that both hypercholesterolaemia and ApoE regulate the intensity of in-vivo systemic autoimmune responses.
© 2016 British Society for Immunology.

Entities:  

Keywords:  ApoE; LDLR; collagen type II-induced arthritis; hypercholesterolaemia

Mesh:

Substances:

Year:  2016        PMID: 27571306      PMCID: PMC5108071          DOI: 10.1111/cei.12857

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Lipid profiles in untreated patients with rheumatoid arthritis.

Authors:  Y B Park; S K Lee; W K Lee; C H Suh; C W Lee; C H Lee; C H Song; J Lee
Journal:  J Rheumatol       Date:  1999-08       Impact factor: 4.666

2.  Apolipoprotein E suppresses the type I inflammatory response in vivo.

Authors:  Kamilah Ali; Melissa Middleton; Ellen Puré; Daniel J Rader
Journal:  Circ Res       Date:  2005-09-22       Impact factor: 17.367

3.  Apolipoprotein E induces antiinflammatory phenotype in macrophages.

Authors:  Daniel Baitsch; Hans H Bock; Thomas Engel; Ralph Telgmann; Carsten Müller-Tidow; Georg Varga; Martine Bot; Joachim Herz; Horst Robenek; Arnold von Eckardstein; Jerzy-Roch Nofer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-02-24       Impact factor: 8.311

4.  Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis.

Authors:  M Van Oosten; P C Rensen; E S Van Amersfoort; M Van Eck; A M Van Dam; J J Breve; T Vogel; A Panet; T J Van Berkel; J Kuiper
Journal:  J Biol Chem       Date:  2001-01-02       Impact factor: 5.157

5.  Exacerbation of type II collagen-induced arthritis in apolipoprotein E-deficient mice in association with the expansion of Th1 and Th17 cells.

Authors:  Jorge Postigo; Fernanda Genre; Marcos Iglesias; Maigualida Fernández-Rey; Luis Buelta; José Carlos Rodríguez-Rey; Jesús Merino; Ramón Merino
Journal:  Arthritis Rheum       Date:  2011-04

6.  Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity.

Authors:  M E Kelly; M A Clay; M J Mistry; H M Hsieh-Li; J A Harmony
Journal:  Cell Immunol       Date:  1994-12       Impact factor: 4.868

7.  Dyslipoproteinemia in the course of active rheumatoid arthritis.

Authors:  M B Lazarevic; J Vitic; V Mladenovic; B L Myones; J L Skosey; W I Swedler
Journal:  Semin Arthritis Rheum       Date:  1992-12       Impact factor: 5.532

8.  Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma.

Authors:  Y Zhu; S Bellosta; C Langer; F Bernini; R E Pitas; R W Mahley; G Assmann; A von Eckardstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

9.  ApoE deficiency exacerbates the development and sustainment of a semi-chronic K/BxN serum transfer-induced arthritis model.

Authors:  Amy M Archer; Rana Saber; Shawn Rose; Alexander Shaffer; Alexander V Misharin; FuNien Tsai; G Kenneth Haines Iii; Salina Dominguez; Mesut Eren; Douglas E Vaughan; Carla M Cuda; Harris Perlman
Journal:  J Transl Med       Date:  2016-06-10       Impact factor: 5.531

10.  Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury.

Authors:  Yumiko Imai; Keiji Kuba; G Greg Neely; Rubina Yaghubian-Malhami; Thomas Perkmann; Geert van Loo; Maria Ermolaeva; Ruud Veldhuizen; Y H Connie Leung; Hongliang Wang; Haolin Liu; Yang Sun; Manolis Pasparakis; Manfred Kopf; Christin Mech; Sina Bavari; J S Malik Peiris; Arthur S Slutsky; Shizuo Akira; Malin Hultqvist; Rikard Holmdahl; John Nicholls; Chengyu Jiang; Christoph J Binder; Josef M Penninger
Journal:  Cell       Date:  2008-04-18       Impact factor: 41.582

View more
  1 in total

Review 1.  Immunologic Aspects of Dyslipidemia: a Critical Regulator of Adaptive Immunity and Immune Disorders.

Authors:  Daehong Kim; Hayeon Chung; Jeong-Eun Lee; Jiyeon Kim; Junseok Hwang; Yeonseok Chung
Journal:  J Lipid Atheroscler       Date:  2021-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.